Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy-Reference-Cited by-同舟云学术

Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy

Published:2019-12 Issue:12 Volume:19 Page:763-775.e2
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Emond Bruno,Sundaram Murali,Romdhani Hela,Lefebvre Patrick,Wang Song,Mato Anthony

Funder

AbbVie

BeiGene

DTRM

Sunesis

TG Therapeutics

Janssen Scientific Affairs, LLC

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

2. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;N Engl J Med,2014

3. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial;Hillmen;Lancet,2015

4. Chronic lymphocytic leukaemia;Hallek;Lancet,2018

5. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma version 1.2017;National Comprehensive Cancer Network,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting;JCO Oncology Practice;2024-08

3. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia;Journal of Managed Care & Specialty Pharmacy;2024-05

4. Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US;The Oncologist;2024-01-27

5. Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran;Value in Health Regional Issues;2023-11